Comparability

Comparability is the formal demonstration that a product’s quality, safety, and efficacy are unaffected by a manufacturing change. It matters most for biologics because the process largely defines the product: a change to the cell line, medium, purification, formulation, or scale can alter glycosylation, aggregation, or charge variants in ways that a specification alone will not reveal.

ICH Q5E frames it as a stepwise exercise. It begins with analytical comparability — an orthogonal package of physicochemical and biological characterisation, plus stability data, comparing pre- and post-change material against pre-defined acceptance criteria. Where analytical data alone cannot resolve the question, or where the change is substantial and occurs late in development, non-clinical or clinical data may be needed.

The decisive point is that criteria are set before the study, not after the results arrive. Comparable does not mean identical — it means any differences observed have no adverse impact on quality, safety, or efficacy, and that conclusion must be justified rather than asserted. The same logic underpins biosimilar development, where comparability is run against a reference product rather than against a firm’s own earlier process.

• —Demonstrates a manufacturing change has not adversely affected quality, safety, or efficacy.
• —Stepwise: analytical characterisation and stability first; non-clinical or clinical data only if needed.
• —Acceptance criteria are pre-defined — set before the data arrive, not after.
• —Comparable ≠ identical; differences must be shown to have no adverse impact.
• —Most consequential for biologics, where the process largely defines the product.
• —The same framework underpins biosimilar comparability against a reference product.

ICH Q5E (Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process); supported by ICH Q5A(R2) for viral safety, Q6B for specifications, and Q12 for lifecycle change management.